Quell Therapeutics’ Post

Trivia is the plural of the Latin word trivium, meaning “a place where three roads meet” i.e., a crossroad. Every other week EpicentRx team members gather not at a place where three roads meet but virtually on Zoom where host and moderator, Dr. Tony Reid, CEO of EpicentRx, presents company-related information and asks fun and interesting questions. These questions prove that not all trivia is trivial, as they most often relate to lead therapies, RRx-001 (nibrozetone) and AdAPT-001. Read more in this blog post here: bit.ly/3x2Yp5C

Today, on World Parkinson's Day, we at Prevail Therapeutics pause to reflect on the journey towards empowering those affected by #ParkinsonsDisease (PD).   PD presents unique challenges, impacting millions worldwide. Yet, through our dedication to research and development, we strive to redefine the possibilities for patients and caregivers alike. Our team continues to push the boundaries of science, harnessing new technologies and novel therapeutic approaches to address the complexities of PD. Prevail understands the importance of collaboration and community in combating PD.   At Prevail, we're deeply committed to developing innovative solutions for those with PD. By partnering with healthcare professionals, advocacy groups, and patients themselves, we're forging a united front against Parkinson's, empowering individuals with knowledge, support, and access to advanced treatments.   Together, let's continue to raise awareness, drive innovation, and inspire hope for the Parkinson’s community. To discover more about Prevail’s work with PD, visit our website: https://bit.ly/3QvAYbk #ParkinsonsAwareness #WorldParkinsonsDay

Our Chief Medical Officer, Dr. Fairooz Kabbinavar M.D., FACP, sat down with Clinical Leader to discuss a pivotal moment in Cardiff Oncology’s journey—our decision to transition our lead clinical development program from second-line to first-line RAS-mutated metastatic #colorectalcancer. In this Q&A, Dr. Kabbinavar shares the data that drove this decision, the collaborative conversations with the #FDA, and what this could mean for the future of mCRC treatment and patients. Interested in the strategy behind #clinicaltrial design? Then this interview is a must-read! https://lnkd.in/eMU-DemU #innovation #cancerresearch

I and other members of the Science 37 team will be in Philly for CRAACO: Clinical Research as a Care Option, Mobile in Clinical Trials, and DPHARM: Disruptive Innovations to Modernize Clinical Research the week of 15 September. Let's connect to discuss doing what we do, not because it's easy but because it's the right thing to do to advance access to life changing therapies! #decentralizedtrials #patientcentric #patientaccess

Exciting to hear about the advances in lung cancer research and treatment modalities in development for ALK positive lung cancer. #alkpositive #research #lungcancerresearch

🎉 MedTech Innovator winners extend the time continuum of stroke care. 🏆 MedTech Innovator officially ended its 2023 cohort with the announcement of awards presented to innovative medtech companies in its accelerator program. In each category, the best of the best were chosen by a live audience after a pitch competition (see Figure 1 below). 🧠 Among the 2023 #MedTechInnovator award winners are two companies working in stroke, from opposite ends of the treatment spectrum. StrokeDx has a point-of-care diagnostic for the hospitalized acute stroke patient, and MicroTransponder restores lost abilities to chronic stroke patients, even years after the event. 📖 Learn more here: https://bit.ly/4b5LnEa 📸 Source: MedTech Innovator; company websites (We feature two of the top winners in separate articles this month: StrokeDx and MicroTransponder, both focusing on stroke care. StrokeDx received the highest honor, a $350,000 award as the grand prize winner of the Global Competition, with MicroTransponder garnering $200,000 as the winner of the first ever competition honoring mid-stage companies.) #medtechinnovation #medtechindustry #medtech #medicaldevices #stroketreatment

The Future of Healthcare: Digital Therapeutics in Clinical Research The integration of digital therapeutics in clinical research is a game-changer! Learn how these software-based interventions are enhancing patient engagement, improving data collection, and driving better health outcomes. Read our new blog to find out more. #HealthcareInnovation #DigitalTherapeutics #ClinicalTrials

🔬At Neuronity, we are exploring innovative #genetherapy approaches in our pre-clinical trials, setting the stage to revolutionize #Parkinsondisease treatment. Under the visionary leadership of our CEO, Hyun Joon Lee we're crafting game-changing strategies that promise to transform care for #Parkinson’s patients. Our goal is clear: advance groundbreaking #genetherapy to make a significant impact! 💡🧬 #ParkinsonsDisease #GeneTherapy #PreClinicalResearch #AAVgenetherapy #Lentivirusgenetherapy

In the dynamic world of clinical research, the synergy between sponsors and CROs is pivotal to driving innovation and achieving successful outcomes. At WEP Clinical, we believe that a collaborative approach is the cornerstone of advancing clinical development, especially in the realm of advanced therapies, rare disease, and early-phase trials. By fostering open communication, mutual respect, and a shared vision, sponsors and CROs can navigate the complexities of clinical trials more effectively. This partnership not only accelerates the development process but also ensures that patient-centric solutions are at the forefront of our efforts. Together, we can overcome challenges, leverage our collective expertise, and bring groundbreaking therapies to those who need them most. Let’s continue to innovate, inspire, and make a positive impact on the lives of patients worldwide. #WEPClinical #PatientAccess #ClinicalResearch #Collaboration #Innovation #RareDiseases